Medicure Inc.
1200 Waverley Street
Suite 4
Winnipeg
Manitoba
R3T 0P4
Canada
Tel: 204-487-7412 or 888-435-2220
Fax: 204-488-9823
Website: http://www.medicureinc.com/
Email: info@medicureinc.com
229 articles about Medicure Inc.
-
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
4/4/2024
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time.
-
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
12/5/2023
Medicure Inc. through its pharmacy subsidiary Marley Drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY® tablets, a sodium-glucose cotransporter-2 inhibitor, at an affordable cash price delivered directly to patient homes in all 50 US states and territories.
-
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
11/23/2023
Medicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridoxine 5′-phosphate oxidase deficiency.
-
Medicure Reports Financial Results for Quarter Ended September 30, 2023
11/21/2023
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2023.
-
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
8/29/2023
Medicure Inc. reaffirms its commitment to providing affordable and straightforward access to its branded pitavastatin, ZYPITAMAG®, to people living with HIV through two important channels: its pharmacy subsidiary Marley Drug® and through the AIDS Drug Assistance Program Crisis Task Force formulary.
-
Medicure Reports Financial Results For Quarter Ended June 30, 2023
7/28/2023
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2023.
-
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
7/24/2023
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time.
-
Medicure Reports Financial Results for Quarter Ended March 31, 2023
5/26/2023
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter ended March 31, 2023.
-
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2022
4/6/2023
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter and year ended December 31, 2022.
-
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
4/5/2023
Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2022 Year End Financial Results on a Conference Call on April 10, 2023 at 8:30 am Eastern Time.
-
MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS
2/1/2023
Medicure Inc. announced today that Gerald McDole , a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.
-
Medicure Reports Financial Results for Quarter Ended September 30, 2022
11/24/2022
Medicure Inc. reported its results from operations for the quarter ended September 30, 2022.
-
Medicure to Present Financial Results on November 25, 2022 Call at 8:30 am ET for Quarter Ended September 30, 2022
11/17/2022
Medicure Inc. will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time.
-
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022
8/24/2022
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2022.
-
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
8/17/2022
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time.
-
Medicure Announces Results of 2022 AGM
6/20/2022
Medicure Inc. is pleased to announce that the following individuals were elected as directors at its Annual General Meeting of shareholders held on June 16, 2022: Dr. Albert Friesen, Gerald McDole, Brent Fawkes, Dr. Arnold Naimark, Peter Quick and James Kinley.
-
Medicure Reports Financial Results for Quarter Ended March 31, 2022 and Appointment of Haaris Uddin as Chief Financial Officer
5/31/2022
Medicure Inc. reported its results from operations for the quarter ended March 31, 2022, and is pleased to also announce the appointment of Mr. Haaris Uddin as Chief Financial Officer, effective June 1, 2022.
-
Medicure Reports Financial Results For Quarter And Year Ended December 31, 2021
4/28/2022
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter and year ended December 31, 2021.
-
Medicure To Report Financial Results For Year Ended December 31, 2021 On April 28th At 7:30 AM CST
4/26/2022
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announces Medicure's 2021 Year End Results Conference Call.
-
Medicure Reports Financial Results for Quarter Ended September 30, 2021
11/22/2021
Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2021.